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Background: Locoregional recurrence is the typical pattern of recurrence in gastric cancer, and cannot be removed
by surgery in most of the patients. We aimed to evaluate the feasibility and efficacy of computed tomography
(CT)-guided brachytherapy for patients with locoregional recurrent gastric cancer.
Materials and methods: We reviewed the case histories of 28 patients with locoregional recurrent gastric cancer
that were selected for CT- guided brachytherapy by a multidisciplinary team. The clinical data of the patients
including patient characteristics, treatment parameters, short-term effects, and survival data were collected and
analyzed.
Results: 15-75 125I seeds were implanted into each patient to produce a minimal peripheral dose (MPD) 100-
160 Gy. Median day 0 dosimetry was significant for the following: V100 (the volume treated with the prescription
dose) 95.8% (90.2-120.5%) and D90 (prescription dose received by at least 90% of the volume) 105.2% (98.0-124.6%)
of prescription dose. No serious complications occurred during the study. Two months after brachytherapy,
complete response, partial response and progressive disease were observed in 50.0%, 28.6% and 21.4% of patients,
respectively. The median survival time was 22.0 ± 5.2 months, and the 1, 2,and 3-year survival rate was 89 ± 6%,
52 ± 10% and 11 ± 7%, respectively. A univariate analysis showed that the tumor size was a significant predictor
of overall survival (P= 0.034). Patients with tumors <3 cm had relatively higher complete response rate (66.7%),
compared to those with tumors >3 cm (30.8%). The PTV (planning target volume) smaller than 45 cm3 was
significantly correlated with achieving complete tumor eradication in the treated region (P= 0.020).
Conclusions: For selected patients with limited locoregional recurrent gastric cancer, CT-guided brachytherapy
using 125I seeds implantation can provide a high local control rate, with minimal trauma.
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Despite a remarkable decline of the incidence during the
second half of the 20th century, gastric cancer still
remains as the fourth most common cancer worldwide
and the second most common cause of cancer-related
death [1]. Nearly two-thirds of gastric cancer cases occur
in developing countries and 42% in China alone [2]. The
prognosis of locally advanced gastric cancer remains* Correspondence: wcpjjt@163.com; jjtnew@163.com
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reproduction in any medium, provided the ordismal even after potentially curative resection, adjuvant
chemotherapy and radiotherapy [3]. The 5-year overall
survival (OS) rates remain between 30% to 40% [3,4].
Tumor recurrence is the main cause of the failure of
treatment. Prospective studies have shown that the
recurrence of gastric cancer was most commonly involved
with locoregional recurrence, heamatogenous metastasis,
and peritoneal lesions [5-7]. Most of the patients with
recurrent gastric cancer present advanced progression,
such as multiple heamatogenous metastasis, extensive
lymphatic. In such cases, systemic chemotherapy is the
only potential treatment available to patients. However, for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vival benefit may be expected from local treatment such
as surgery [8,9], and external beam radiotherapy (EBRT)
[10,11], as opposed to systemic chemotherapy alone.
Brachytherapy (permanent implantation of radioactive
seed) has emerged as an alternative local treatment for
solid tumors, and is widely applied for its curative
effects, minimal trauma, and few associated complica-
tions [12-17]. In this study, we aimed to evaluate the
feasibility and efficacy of computed tomography (CT)-
guided brachytherapy for selected patients with locore-
gional recurrent gastric cancer. Our group included
those with: solitary recurrence at the primary tumor bed,




Patient inclusion criteria include: 1). Gastric cancer
patients with limited locoregional recurrence including
solitary recurrence at primary tumor bed, solitary intra-
abdominal peritoneal recurrence, and single regional
lymph node recurrence (no more than 3 lymph nodes)
based on diagnosis by CT, and confirmed by percutaneous
puncture biopsy; 2). A performance score of no more than
2 according to the criteria of the Eastern Cooperative
Oncology Group (ECOG); 3). Absence of intraluminal
recurrence determined by gastroscope; 4). No previous
history of abdominal radiotherapy. Whether CT-guided
brachytherapy was indicated in a patient was determined
by the Gastric Cancer Collaborative Group (GCCG) of
the hospital, which was composed of a medical oncologist,
radiologist, surgeon, and intervention specialist. The mul-
tidisciplinary assessment included the potential value of
brachytherapy in improving local control and survival,
the risks of seed implantation, the identification of vital
structures surrounding the recurrent tumor, and the
accessibility of safe puncture ways to ensure an optimal
dose distribution in the treatment area.
All the patients provided informed consent, which was
approved by the Ethics Committee of the Third
Affiliated Hospital of Soochow University.
Instruments and materials
CT scanning machine: 16-spiral CT scanner (Siemens)
and Treatment planning system (TPS): HGGR-2000
(Hokai Medical Instrument Co., Ltd, ZhuHai, China), Im-
plantation instruments: 18-G needles (Dr.J, Japan) and im-
plantation gun (JACO Pharmaceutical Co., Ltd, NingBo,
China), 125I sealed seed sources (JACO Pharmaceutical
Co.,Ltd, NingBo, China). The seeds were manufactured
from silver rods, which absorbed 125I, and were enclosed
in a laser- welded titanium capsule. Each seed was
0.8 mm in diameter, 4.5 mm in length and had a capsulewall thickness of 0.05 mm. The 125I produces gamma rays
(24-35 keV) with a half-life of 59.6 days, half-value thick-
ness of 0.025 mm of lead, penetration of 17 mm, incipient
rate of 7 cGy/h, and activities of 0.5-0.8 mCi. All 125I seeds
were mailed to our hospital in a type-A pack that passed
through leak detection and activity tests.
CT-guided implantation protocol
The three-dimensional images of the tumor were recon-
structed with the TPS based on data from CT images.
PTV (planning target volume) was defined as GTV
(gross tumor volume) plus 0.5-1.5 cm in each direction.
PTV was covered by 90% of isodose curves. This dose
was prescribed as the minimal peripheral dose (MPD)
encompassing the PTV. The total seeds strength that
needed to be implanted was calculated by the TPS. Seeds
were implanted at least 1.0 cm away from the intestinal
wall, and the maximum 2 cm3 dose to small intestine
was lower than 60 Gy. In practice, 15% more seeds
were implanted than planned to ensure the maximum
radiation effect.
Patients fasted for 24 h prior to the operation, and oral
laxatives were given 12 h before the procedure. Patients
received intramuscular injection of diazepam (10 mg)
and anisodamine (10 mg) 30 minutes before the oper-
ation. All the brachytherapy implants were performed in
a standard CT room. Before the implantation procedure,
the patient underwent scanning at reconstruction inter-
vals of 5 mm and dual-phase enhanced-contrast. A safe
puncture path was carefully determined according to the
CT images. Our preferred puncture paths were natural
gaps or spaces such as the paraspinal or perirenal spaces.
In addition, in cases where tumors were located in the
porta hepatic or near the right wall of abdominal aorta,
we penetrated the liver. For tumors in the omentalis or
the head of the pancreas we traversed the stomach; and
for tumors in the hilum of the spleen on in the tail of
the pancreas, we traversed the colon. The puncture
points on the skin were marked according to CT images.
The abdominal wall was anesthetized with 2% lidocaine.
For the puncture procedure, the patient was instructed
to hold his/her breath at the end of a normal expiration.
The needle was placed to a depth determined at each
point by the CT scan. Repeated CT scanning at intervals
of 5 mm with needle in place permitted the adjustment of
depth and angle of needle direction, and avoided punctur-
ing vessels, pancreatic duct and bile duct. Adjacent nee-
dles were separated by about 1.0-1.5 cm. The 125I seeds
were inserted through each needle by using the implant-
ation gun. Each needle was withdrawn 0.5-1.0 cm, and
another radioactive seed was inserted. Post-placement
CT was performed to document the distribution of seeds
in the tumor immediately after seed implantation. The
practical radiation dose was validated by the TPS. The
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(prescription dose received by at least 90% of the volume)
and V100 (the volume treated with the prescription dose)
were recorded. In case of an unsatisfactory dose distribu-
tion, the optimization parameters were adjusted and the
calculation was repeated using the TPS. Additional 125I
seed implant will be performed immediately if puncturing
the low-dose region in PTV was feasible.
Continuous treatment after seeds implantation
When a residual tumor or a new solitary locoregional
recurrence was detected after brachytherapy, repeated
seed implantation might be performed in the patient
after reassessment. Although most patients with recur-
rent gastric cancer have a prior history of chemotherapy
after surgery, fluoropyrimidine-based chemotherapy was
routinely recommended after brachytherapy.
Evaluation of the short-term effects and follow up
Assessment for tumor response was carried out 2 months
after the 125I seeds implantation. Complete response
(CR, no residual tumor in the area with radioactive seeds
completely gathering together), partial response (PR),
stable disease (SD) and progressive disease (PD) were
reported according to the Response Evaluation Criteria
in Solid Tumors (RECIST). The overall response rate
(ORR) was the sum of CR and PR.
Follow-up was performed every 3 months after 125I
seeds implantation. Follow-up consisted of physical exam-
ination, spiral computed tomography or ultrasonography,
chest radiography, serum biochemistry, and clinical exam-
ination. Gastroscopy was also performed for patients
in whom intraluminal recurrence was suspected. The
median follow-up period was 22 months, ranging from
7 to 39 months.
Statistical analysis
Overall survival (OS) was defined as the time from the
date of brachytherapy to the date of death from any cause
or the date of the last follow-up. Participants who were
alive at the end of the study period were considered cen-
sored. Progression-free survival (PFS) was defined as the
time-period from the date of operation to the date of the
first tumor progression or the date of last follow-up. Par-
ticipants who were recurrence-free were considered cen-
sored. Continuous data are presented as media ±
Standard Deviation. The 1-, 2- and 3-year survival rates
were estimated using the Life Table method. The OS
curve was estimated using the Kaplan–Meier survival
analysis. The following variables were assessed as poten-
tial predictors in univariate Cox models of survival: age,
gender, time to recurrence, original TNM stage and
tumor size. A minimum P value approach was used to
determine the optimal cut-off points to dichotomizecontinuous variables of interest, and corresponding P
values were adjusted using Miller and Siegmund adjust-
ment [18]. Data were analyzed using SPSS software (version
13.0, SPSS Inc., Chicago, IL, USA.).
Results
Enrollment
From July 2007 to June 2011,209 patients were diag-
nosed as having recurrence after gastrectomy for gastric
cancer at our hospital. 38 patients (18.1%) presented
with limited locoregional recurrence. 3 patients were
excluded from seed implantation because the tumor
position was not easily accessible to needle puncture
(2 patients had tumors located in the gap between the
aorta and inferior vena cava and 1 patient had a tumor
located in the space between the aorta and the superior
mesenteric artery). 2 patients were considered unsuitable
for brachytherapy due to poor physical health. The
remaining 33 (86.8%) of 38 patients were assessed suitable
for seed implantation. Among the 33 patients, 3 patients
received EBRT, 2 patients received surgery, and 28 patients
eventually received CT-guided brachytherapy.
The study included 18 males and 10 females ran-
ging in age from 42 to 83 years old. Solitary extra-
luminal recurrence was found in 13 patients, and a
single regional lymph node recurrence in 15 patients.
The average time to recurrence was 18.0 ± 6.2 months
(ranging from 7 to 36 months). 23 patients under-
went D2 gastrectomy, and 5 patients underwent D1
gastrectomy. 24 patients received adjuvant chemo-
therapy after surgery. The details of the patient char-
acteristics are shown in Table 1.
Response and survival
All the target tumors were responsive to the treatment
2 months after 125I seeds implantation. The evaluation
of the short-term effects was as follows: CR occurred in
14 cases (50.0%), PR in 8 cases (28.6%), and PD in 6
cases with recurrences in new sites (21.4%) (Lymph node
metastasis occurred in 3 cases, peritoneal metastasis
occurred in 2 cases, and hepatic metastasis occurred
in 1 case). ORR for this group of patients was 78.6%.
13 patients (46.4%) had residual tumor in the initial
region. One typical patient’s TPS planning progamm and
CT scans during follow-up are shown in Figure 1.
At the end of follow-up, 20 patients had died. The
median overall survival time was 22.0 ± 5.2 months for
all patients, and the 1, 2 and 3-year survival rate was
89 ± 6%, 52 ± 10% and 11 ± 7%, respectively (Figure 2).
Univariate Cox regression analysis showed that tumor
size was a significant predictor for OS (P= 0.034). A cut-
off point of 3 cm for the longest tumor diameter was
found to be most useful in separating patients in terms
of their survival, with patients having a tumor size less
Table 1 Patient characteristics
Case Age/
sex


















1 59/M head of pancreas 30 7 TG T4N1M0 lower D2 intestinal yes
2 65/M omental bursa 50 11 PG T3N1M0 lower D2 intestinal yes
3 62/F omental bursa 50 18 PG T2N2M0 middle D2 intestinal yes
4 83/M porta hepatis 25 32 PG T2N1M0 lower D1 intestinal no
5 45/F tail of pancreas 60 16 TG T4N2M0 middle D2 diffuse yes
6 66/M PALN 25 28 PG T3N2M0 upper D2 intestinal yes
7 49/M PALN 35 17 PG T3N1M0 lower D2 intestinal yes
8 79 M hilum of spleen 28 10 PG T2N2M0 lower D1 intestinal yes
9 67/F omental bursa 25 14 TG T3N1M0 lower D2 diffuse yes
10 72/M omental bursa 45 13 PG T2N1M0 upper D2 intestinal no
11 49/M head of pancreas 25 14 PG T3N1M0 lower D2 intestinal yes
12 42/M porta hepatis 40 16 PG T3N1M0 middle D2 diffuse yes
13 66/M porta hepatis 22 19 PG T3N1M0 lower D2 intestinal yes
14 72/F head of pancreas 38 10 TG T4N1M0 lower D1 diffuse yes
15 63/M PALN 20 26 PG T2N1M0 upper D2 intestinal yes
16 70/M omental bursa 26 18 TG T4N0M0 lower D2 diffuse yes
17 62/F omental bursa 55 24 PG T3N1M0 middle D2 intestinal yes
18 45/F tail of pancreas 43 20 PG T2N2M0 lower D2 intestinal yes
19 55/F PALN 52 16 PG T1N2M0 upper D1 intestinal yes
20 58/M PALN 22 30 PG T3N1M0 lower D2 intestinal yes
21 71/M hilum of spleen 45 9 TG T$N2M0 lower D2 diffuse yes
22 62/F omental bursa 48 24 TG T3N1M0 middle D2 intestinal yes
23 45/M PALN 25 23 PG T2N1M0 lower D2 intestinal yes
24 68/F tail of pancreas 38 32 PG T2N1M0 lower D2 intestinal yes
25 71/M PALN 35 36 PG T2N1M0 upper D2 intestinal no
26 76/M porta hepatis 22 24 PG T4N0M0 upper D1 intestinal yes
27 49/F omental bursa 30 11 TG T3N2M0 middle D2 diffuse yes
28 79/M PALN 20 14 PG T3N1M0 lower D1 intestinal no
PALN:para-aortic lymph node; TG: total gastrectomy; PG: partial gastrectomy; TNM stage: International Union Against Cancer (UICC 2002) TNM system; LN:
lymph node; CT: chemotherapy.
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vival (P= 0.026, Figure 3). The median survival time was
30.0 ± 5.1 months in the tumor size <3 cm group, and it
was 17 ± 5.0 months in the >3 cm group. Patients with
tumor size <3 cm had relatively higher complete
response rate (66.7%, 10/15) compared to the patients
with tumor size >3 cm (30.8%, 4/13).
During the follow-up, disease progression was
detected in 27 patients. The median progression-free
survival (PFS) after CT-guided brachytherapy was
11.4 ± 4.6 months, the 1, 2 and 3-year PFS rate was
50 ± 9%, 11 ± 6% and 4 ± 4%, respectively. Metastasis
to other region was the most frequent recurrent pat-
tern in the study. The first progression pattern after
brachytherapy was extensive lymph node metastasis
(9 cases), single regional lymph node recurrence (3 cases),
heamatogenous metastasis (8 cases), ascites (3 cases),remnant stomach recurrence (1 case), multiple recurrence
(3 cases), and progression in the initial recurrent region
(2 cases). The median time to metastases to other
regions was 13.5 ± 5.5 months in the tumor size <3 cm
group, and 9.0 ± 3.5 months in the >3 cm group.
Treatment parameters and complications
A total of 1145 seeds were implanted. The median PTV
was 35.49 cm3 (ranging from 20.15 to 113.04 cm3). 15-
75 (median 40) of 125I seeds were implanted into
each patient to achieve MPD 100-160 Gy (median
120 Gy). 2-10 (median five) needle punctures were per-
formed to distribute seeds into the tumors. Median day
0 dosimetry was as follows: V100 95.8% (90.2-120.5%)
and D90 105.2% (98.0-124.6%) of prescription dose. The
treatment parameters are shown in Table 2. In addition,
the relationship of the dose-volume parameters to tumor
Figure 1 TPS planning diagram and CT scans during follow-up with recurrence in the primary tumor bed after total gastrectomy.
a). Before treatment, the tumor size was 35 mm in diameter; b). Isodose curves for treatment planning (“iso” 120 Gy, red line = 150%; green
line =100%; yellow line = 50%); c). Sagittal images reconstructed by the TPS based on data from perioperation CT images: the skyblue area
represent the PTV; d). Three-dimensional view of the TPS planning program: four puncture paths were designed; 99.0% of PTV (the skyblue area)
was covered by 90% of isodose curves (the pink area); e). A typical CT slice showing the distribution of 125I seeds and isodose curves after seed
implantation (red line = 180 Gy; green line =120 Gy; yellow line = 60 Gy); f). The D0 dose-volume histogram caculated by TPS (V100 = 96.2%,
D90= 117%); g). Two months after treatment, the recurrent tumor was completely eradicated, and 125I seeds gathered together; h). Six months
after treatment, there was no progression in the treatment region, and some seeds migrated.
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cantly related to response of the target tumor. The
complete response of target tumor was 25.0% (3/12) in
patients with PTV≥ 45 cm3, compared with 75.0% (12/
16) in patients with PTV<45 cm3 (P=0.020). The
V100 higher than 95% was associated with achieving
complete tumor eradication, but the difference was not
statistically significant (P=0.056). Two month after seed
implantation, 11 (73.3%) of 15 patients with V100≥ 95%achieved complete response in the treated region, com-
pared with 4 (30.8%) of 13 patients with V100< 95%.
The relationship between tumor response and D90 was
no significant at any cut-point analyzed.
Percutaneous puncture was carried out via the following
methods: 1). Through the paraspinal space (in 10 cases); 2).
Through the perirenal space or gaps between the stomach
and intestinal tract (in 9 cases); 3. Penetrating the liver (in 4
cases); 4). Traversing the stomach (in 8 cases); 5).
Figure 2 Kaplan-Meier estimates for overall survival (OS) for patients. The median survival time was 22.0 ± 5.2 months.
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approaches were shown to be safe without serious compli-
cations such as haemorrhage, bile fistula, pancreatic fistula,
and peritonitis. No patients died of perioperative complica-
tions. The mean hospital staying after treatment was
3.2 days (median 3±0.5 days). During the follow-up, 14
(1.22%) of 1145 seeds had migrated in 3 (10.7%) of 28
patients. 6 (0.52%) seeds had migrated to the peritoneal
cavity in one patient and 8 (0.70%) to liver in 3 patients. No
adverse effects were observed in the 3 patients with seed
migration. The common side-effects of radiotherapy such
as gastrointestinal reactions and bone marrow depression
were not observed before commencing chemotherapy.
There was also no gastrointestinal bleeding or perforatin in
the study.
4 patients received a second operation two months
after the first seeds implantation (2 patients within the
first brachytherapy PTV and 2 patients in para-aortic
lymph node recurrence). The mean PTV of the second
brachytherapy was 12.0 cm3 (5.5-20.8 cm3), and the
average number of seeds implanted was 22 (ranging
from 8 to 35). 24 patients received palliative chemother-
apy based on Xeloda (n = 11) or S-1 (n = 13) after
brachytherapy. The median duration of chemotherapy
was 4 months (ranging from 2 to 10 months).
Discussion
Local or regional recurrence in the tumor bed, the anas-
tomosis, or regional lymph nodes occurs in 40- 65%
of patients after gastric resection with curative intent[19,20]. Intraluminal local recurrence is rare but cur-
able in 50% of cases without distant metastases.
However, extraluminal locoregional recurrence com-
prises the major portion of recurrence and cannot be
removed in most patients [21]. During the four years
of recruitment for the trial, 28 patients diagnosed with
limited extraluminal locoregional recurrent gastric cancer
received CT-guided seed implantation in our hospital.
Most of the recurrent tumors were located in or near the
primary tumor bed, such as the bursa omentalis, the head
of pancreas, the tail of pancreas, and the retroperitoneal
lymph node. In this study, we demonstrated the clinical
effectiveness of CT-guided brachytherapy as a salvage ther-
apy for extraluminal locoregional recurrent gastric cancer.
Permanent implantation of radioactive seeds has
emerged as a microinvasive local treatment modality,
which has been successfully applied to many solid tumors
such as prostate cancer, pancreatic cancer, non-small-cell
lung cancer and metastatic tumors [13,16,22-24]. Percu-
taneous image-guided seeds implantation that can be
performed without surgery or general anesthesia has
attracted attention because of the advantages it offers in
increasing the dose of radiation administered to tumors,
without damaging neighboring organs [25]. With this
technique, highly effective radiation doses are applied as
a single fraction, ensuring protracted cell killing over a
period of several weeks or even months. Compared to
other interventional procedures, the advantages include:
interference-free and accurately predictable energy distri-
bution, treatable size of a target lesion, and lower rate of
Figure 3 Kaplan-Meier estimates of OS for patients divided into two subgroups according to tumor size (P=0.026, log-rank test).
Continuous line: patients with tumor < 3 cm; dotted line, patients with tumor >3 cm .
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[14,16]. Prior and during the seeds implantation proced-
ure, we carefully designed and chosed the safest paths for
needle insertion. We used the natural gaps between
organs as much as possible, followed by penetrating the
liver and transversing the stomach or colon when. The
potential complications of the treatment, including haem-
orrhage, bile fistula, pancreatic fistula, and peritonitis did
not occurred in the study. Although Shah AP et al. [26]
reported that bowel puncture did not correlate with the
occurrence of acute or late toxicity, we rarely inserted
the implant needles through the bowel. In our study, all
the operations for radioactive seeds implantation were
performed successfully under CT-guidance. No serious
complications during the course of treatment.Table 2 Treatment parameters
Parameter Median Range
GTV (cm3) 14.58 3.23-58.65
PTV (cm3) 35.49 20.15-113.04
MPD (Gy) 120 100-160
D90 (% of prescription dose) 105.2 98.0-124.6
V100 (% of PTV) 95.8 90.2-120.5
No. of seed 40 15-75
Puncture tracks 5 2-10
Activity of seed (mCi) 0.7 0.5-0.8
Total activity (mCi) 28.0 10.5-52.5
GTV: Gross Tumor Volume;PTV: Planning Target Volume; MPD:matched
peripheral dose; PD prescription dose.Surgery and external beam radiotherapy (EBRT) are
the main local treatment modalities that have been
examined in the past studies. Due to the small number
of cases suitable for local treatment, as well as the nature
of the available treatments, it is challenging to design
and complete a randomized prospective study on the
local treatment of locoregional recurrent gastric cancer.
Although surgery is often recommended for the local
recurrence of gastric cancer, the percentage of patients
with locoregional recurrent gastric cancer in whom sur-
gery can be attempted is low [27-29]. In the group stud-
ied by Yoo et al. [6], the proportion of patients treated
with curative surgery was only at 3.7%. Carboni et al.
[30] assessed 38 patients with solitary locoregional
recurrent gastric cancer for macroscopical resection.
The results showed that only 5 patients with intralum-
inal recurrence and 1 patient with extraluminal recur-
rence were resected with curative intent. However,
postoperative complications occurred in two patients,
and one patient died 35 days after surgery. Carboni et al.
suggested that surgery plays a very limited role in the
treatment of isolated locoregional recurrence of gastric
cancer. Nunobe et al. [8] recently reported another retro-
spective study, in which the inclusion criteria were similar
to ours. They reported that the 1, 3, and 5-year survival
rates were 73.0%, 36.7%, and 9.8%, respectively, in 36
patients with solitary locoregional recurrent gastric cancer
treated by surgery combined with chemotherapy. 36.1%
of patients developed postoperative complications, and
the average hospital stay was longer than 30 days
(31.3 ± 5.3 days). Compared to our study, the proportion
Figure 4 Iodine-125 seeds were implanted through percutaneous puncture under CT-guidance: a). Through the paraspinal space; b).
Through the perirenal space between stomach and intestinal tract; c). By penetrating the liver; d). By traversing the stomach. e). By traversing
the colon.
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higher in the Nunobe study (11% versus 36.7%). But the
median survival time is similar (22.0 months versus
23.0 months). However, the percentage of patient suitable
for surgery was not provided in the report, compared to
the typical locoregional recurrence of gastric cancer.
Several clinical trials have confirmed that adjuvant
chemoradiotherapy can prolong the survival of patients
at high risk for recurrence of gastric cancer [3,31,32].
But, few published studies have assessed the efficacy of
external beam radiotherapy (EBRT) to recurrent gastric
cancer. Recently, Sun et al. [10] retrospectively reported
that external beam radiotherapy (EBRT) with delivery of
50 Gy could prolong the survival of patients with
abdominal lymph node (LN) metastases from gastric
cancer. The results showed that the ORR was 83.8%
(CR 29.7%, PR 54.1%), and median survival time was
11.4 months in the radiation group. Stereotactic body
radiotherapy (SBRT) is one of the most advanced radio-
therapy technologies available, and can deliver high, ab-
lative doses of radiation in a limited number offractions. Kim et al [11] reported that SBRT can pro-
duce significant local control in patients with isolated
para-aortic lymph node (PALN) recurrence of gastric
cancer. Since the patients included in our study were
strictly selected with limited extraluminal recurrence,
we consider that SBRT may also be a treatment option
for most these patients if the technology is available.
Another method that allows the delivery a high dose to
tumor beds with minimal exposure of surrounding tis-
sues is intra-operative radiotherapy (IORT). In a retro-
spective study reported by Miller et al. [33], 50 patients
with locally advanced primary or recurrent gastric or
esophageal adenocarcinomas received IORT given as a
single fraction of electron beam radiotherapy (10-25 Gy),
foliowing maximal tumor resection. The results showed
that distant metastatic failure was 79%, local failure was
10%, and regional failure was 15%, and the 1, 2 and 3-
year survival rate was 70%, 40%, and 27%, respectively. In
summary, there is little published data available on radio-
therapy for locoregional recurrent gastric cancer, and
there are no prospective controlled studies that have
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it is still difficult to assess the role of radiotherapy in im-
proving overall survival of patients with recurrent gastric
cancer.
In our study, the tumor size was a significant factor
associated with the overall survival of the patients with
locoregional recurrent gastric caner treated with Iodine-
125 seed brachytherapy. We found that a cut-off point
of 3 cm of the largest tumor diameter was the best way
to separate patients in terms of their survival. As we
know, the local failure of radiotherapy is in part due to
tumor hypoxia and cold spots in tumor subvolumes
[34,35]. With an increase in tumor size, the hypoxic
fraction usually increases, and a concurrent increase in
radiation cold spot is also likely [36]. Since locoregional
recurrent tumors of gastric cancer are often deep-lying
and surrounded by vital structures, only a few needle
paths could be explored for seed implantation in the
study. Therefore, it may be challenging to ensure satis-
factory seed distribution of within the tumor, especially
when the tumor size is larger than 3 cm in diameter. As
a result, cold spots may occur due to the unsatisfactory
distribution of seeds. We reviewed the relationship of
dose-volume parameters to tumor response, and verified
a large PTV and a low V100 were associated with a high
rate of tumor residual. Our results showed that the
larger tumor size not only related to a higher local tumor
residual rate, but also a shorter time to others metasta-
ses. In patients with tumor > 3 cm in size, tumor spread-
ing to other regions occurred earlier than in patients
with smaller recurrent tumors (the median time to other
metastases was 13.5 months vs 9.0 months).This finding
may be explained in two ways. First, a larger tumor size
usually means that the tumor is late-stage, and therefore
more likely to metastases. On the other hand, most of
the patients with larger tumor had residual tumor after
seed implantation, and the failure to completely eradicate
the tumor might lead to subsequent shedding of tumor
cells and a late wave of metastases [37].
A limitation of our study that cannot be ignored is the
lack of a control group with similarly localized tumor
recurrence, which was administered modern systemic
chemotherapy. As our study population was too small
for a randomized trial, it is only possible to compare this
study’s results with those from the chemotherapy stud-
ies. Recently, several pivotal studies have demonstrated
the effectiveness of S-1 based chemotherapy as a first-
line treatment for the advanced or recurrent gastric can-
cer. Koizumi W et al. [38] reported a response rate of
54% (CR 1%, PR 53%), and median survival time of
13 months in patients with advanced gastric cancer who
received S-1 plus cisplatin. Another phase III study
showed a partial response rate of 41.5% (no patients
achieved CR), and a median survival time of 12.8 monthsin patients treated with irinotecan plus S-1 as first-line
treatment [39]. We also should mention that in the
study reported by Shitara K [40], patients with recur-
rent gastric cancer after adjuvant chemotherapy were
included, The response rate was 19.4%, and median
survival time was 12.2 months treated with S-1 plus
cisplatin. Although most of patients (24/28) included
in our study received adjuvant chemotherapy after sur-
gery, we still achieved a response rate of 78.6% (CR
50.0%, PR 28.6%), and the 1-year local control rate in
PTV was 85.7% (24/28). These results may demon-
strate the local control power of brachytherapy using
125I seeds implantation.
Although there was no control group in the present
study treated solely with modern systemic chemother-
apy, we think that CT-guided brachytherapy is effective
in improving local control of the locoregional recurrent
gastric cancer in selected patients. A randomized con-
trolled trial with a larger sample size is needed to further
verify these findings,
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